Mark Iwicki
About Mark Iwicki
Mark Iwicki is a seasoned executive in the biotechnology and pharmaceutical industries, currently serving as Board Chair at Akero Therapeutics and Aerovate Therapeutics, among other roles. He has extensive experience in leadership positions, including his tenure at Novartis and Sepracor, and holds an MBA from Loyola University Maryland.
Current Roles at Nimbus
Mark Iwicki serves as a Director at Nimbus Therapeutics, a position he has held since 2015. His tenure at Nimbus spans over nine years, during which he has contributed to the company's strategic direction and growth. Nimbus Therapeutics focuses on drug discovery and development, utilizing its proprietary platform to create innovative therapies.
Leadership Positions in Biotechnology
Mark Iwicki holds several leadership roles in the biotechnology sector. He has been the Board Chair at Akero Therapeutics since 2018 and at Aerovate Therapeutics, Inc. since 2021. Additionally, he serves as Board Chair at Third Harmonic Bio since 2020. His involvement in these companies reflects his commitment to advancing therapeutic innovations.
Educational Background
Mark Iwicki earned his Master of Business Administration (MBA) from Loyola University Maryland, where he studied Marketing and Finance from 1990 to 1992. He also holds a Bachelor of Science (B.S.) in Business Administration and Management from Ball State University, which he completed from 1985 to 1989. His educational background provides a strong foundation for his career in the pharmaceutical and biotechnology industries.
Previous Experience in Pharmaceuticals
Mark Iwicki has extensive experience in the pharmaceutical industry. He previously worked at Pulmatrix Inc. as Director from 2015 to 2020 and held a similar role at Aimmune Therapeutics during the same period. His career includes significant positions at Novartis Pharmaceuticals, where he led multiple therapeutic areas and served as Vice President of the Cardiovascular Business Unit.
Achievements in the Industry
Mark Iwicki has been instrumental in various successful initiatives in the pharmaceutical sector. He led the sale of Civitas Therapeutics to Acorda Therapeutics in 2014 and provided leadership for the launch of Sunovion Pharmaceuticals following the acquisition of Sepracor by Dainippon Sumitomo Pharmaceuticals. His contributions have significantly impacted the companies he has been involved with.